| [1] |
Bray F,Ren JS,Masuyer E,et al.Global estimates of cancer prevalence for 27 sites in the adult population in 2008[J].Int J Cancer, 2013,132(5):1133-45.
|
| [2] |
Siegel R, DeSantis C,Virgo K,et al.Cancer treatment and survivorship statistics,2012[J].CA Cancer J Clin,2012, 62 (4):220-41.
|
| [3] |
Dorsey K,Agulnik M.Promising new molecular targeted therapies in head and neck cancer[J].Drugs, 2013, 73(4):315-25.
|
| [4] |
Kerbel RS.Tumor angiogenesis[J].N Engl J Med,2008,358(19): 20 39-49.
|
| [5] |
Carmeliet P,Jain RK.Molecular mechanisms and clinical applications of angiogenesis[J]. Nature,2011, 473(7347): 298-307.
|
| [6] |
Sitohy B, Nagy JA, Dvorak HF. Anti-VEGF/VEGFR therapy for cancer: reassessing the target[J].Cancer Res,2012, 72(8): 1909-14.
|
| [7] |
Keefe SM,Cohen MA, Brose MS.Targeting vascular endothelial growth factor receptor in thyroid cancer: the intracellular and extracellular implications[J].Clin Cancer Res,2010, 16(3):778-83.
|
| [8] |
Gotink KJ,Verheul HM.Anti-angiogenic tyrosine kinase inhibitors: what is their mechanism of action?[J].Angiogenesis,2010,13(1): 1-14.
|
| [9] |
Samant RS, Shevde LA. Recent advances in anti-angiogenic therapy of cancer[J]. Oncotarget, 2011, 2(3):122-34.
|
| [10] |
Antonelli A, Fallahi P, Ferrari SM, et al. New targeted therapies for thyroid cancer[J]. Current Genomics, 2011, 12(8): 626-31.
|
| [11] |
Perez CA,Santos ES,Arango BA,et al.Novel molecular targeted therapies for refractory thyroid cancer[J].Head Neck,2012,34(5): 736-45.
|
| [12] |
Nakamura K, Taguchi E, Miura T, et al. KRN951, a highly potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, has antitumor activities and affects functional vascular properties[J]. Cancer Res, 2006, 66(18): 9134-42.
|
| [13] |
Eskens FA, de Jonge MJ, Bhargava P,et al.Biologic and clinical activity of tivozanib (AV-951, KRN-951), a selective inhibitor of VEGF receptor-1, -2, and -3 tyrosine kinases, in a 4-week-on, 2- week-off schedule in patients with advanced solid tumors[J]. Clin Cancer Res, 2011,17(22):7156-63.
|
| [14] |
Wang E,Yin Y,Zhao M,et al.Physiological electric fields control the G1/S phase cell cycle checkpoint to inhibit endothelial cell proliferation[J]. FASEB J, 2003, 17(3): 458-60.
|
| [15] |
Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors[J]. Nat Med, 2003, 9(6): 669-76.
|
| [16] |
Fu Y,Zhang QW.Synthesis of tivozanib hydrochloride monohydrate[J]. Zhongguo Xin Yao Za Zhi,2013,22(1):26-9. [府 莹,张庆文.盐酸替沃扎尼一水合物的合成[J].中国新药杂志, 20 13, 22(1): 26-9.]
|
| [17] |
Schwartz GK. CDK inhibitors: cell cycle arrest versus apoptosis[J]. Cell Cycle, 2002, 1(2):122-3.
|
| [18] |
Paesler J, Gehrke I, Gandhirajan RK,et al. The vascular endothelial growth factor receptor tyrosine kinase inhibitors vatalanib and pazopanib potently induce apoptosis in chronic lymphocytic leukemia cells in vitro and in vivo[J]. Clin Cancer Res, 2010, 16 (13): 3390-8.
|
| [19] |
Sherr CJ,Roberts JM.CDK inhibitors: positive and negative regulators of G1-phase progression[J].Genes Dev,1999,13(12): 15 01-12.
|
| [20] |
Manchado E,Guillamot M,Malumbres M.Killing cells by targeting mitosis[J].Cell Death Differ, 2012, 19(3): 369-77.
|
下载:
